Cutting scans, keeping safety: a new streamlined approach to liver cancer treatment
NCT ID NCT07043387
First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time
Summary
This trial tests a streamlined version of radioembolization, a treatment that delivers tiny radioactive beads directly to liver tumors. The standard procedure requires extra imaging beforehand to check for radiation leakage to the lungs, which can delay treatment. For patients with small tumors (7 cm or less) and no signs of vein invasion, this risk is very low, so the trial skips that extra scan. The goal is to see if this faster, same-day procedure still works well and is safe, measuring tumor response and tracking side effects over a year.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- radioactive microspheres (SIR-Spheres) delivered via radioembolization
- What this could lead to
- If successful, this streamlined approach could make liver cancer treatment faster and more efficient, reducing delays without compromising safety.
- What could go wrong
- The trial is small and observational, so results may not apply broadly. There is a small risk of radiation reaching the lungs, though the study aims to minimize it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Jun 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
patients with metastatic liver cancer or cholangiocarcinoma who are scheduled for radioembolization
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult aged 19 and over * metastatic liver cancer or cholangiocarcinoma * the diameter of the largest tumor ≤ 7cm, tumor number 5 or less * FLR volume \> 30% of total non-tumorous liver volume * Dysmorphic intratumoral vessel : absent, if present, 3mm or thinner ⑥ Child-Pugh class A * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 ⑧ No major organ dysfunction according to blood test performed within two months of study enrollment A. Leukocytes ≥ 1,000/µL and ≤ 20,000/µL B. Hemoglobin ≥ 6.0 g/dL (transfusion allowed to meet this criterion) C. Total bilirubin ≤ 2.0 mg/dL D. Platelet ≥ 40,000/µL E. International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants F. Aspartate transaminase (AST) ≤ 800 IU/L (i.e., ≤ 20X upper normal limit) G. Alanine transaminase (ALT) ≤ 800 IU/L (i.e., ≤ 20X upper normal limit) H. Creatinine ≤ 2.5 mg/dL (If patients is undergoing hemodialysis, no limit of creatinine) ⑨ Patients with a life expectancy of more than 3 months ⑩ For women of childbearing age, a negative serum pregnancy test. ⑪ Patients who have adequately understood the clinical trial and consented in writing Exclusion Criteria: * hepatic vein invasion on dynamic computed tomography (CT) or magnetic resonance imaging (MRI) * Hepatic vein enhancement on arterial phase CT/MRI * dysmorphic intratumoral vessel \> 3mm on arterial phase CT/MRI * TIPS is present * Lobar portal vein enhancement on arterial phase CT/MRI due to AP shunt * main portal vein tumor thrombosis * Cases where the operator judges that the occurrence of even mild radiation pneumonitis could be fatal, based on marked emphysema or interstitial lung disease findings on chest CT * biliary stent or bilioenteric anastomosis * History of severe allergy of intolerance to contrast agents * Contraindication to angiography or selective visceral catheterization
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Cancer Center
NOT_YET_RECRUITINGGoyang-si, South Korea
-
Samsung Medical Center
NOT_YET_RECRUITINGSeoul, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
-
Severance hospital
NOT_YET_RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Burning away bile duct blockages: a new weapon against cholangiocarcinoma?
- Can a Three-Drug chemo cocktail before surgery stop biliary tract cancer from coming back?
- Can a targeted drug combo outsmart bile duct cancer?
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?